Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC
CDC6 is associated with the occurrence and progression of multiple cancer types by regulating the cell cycle. It holds promise as a diagnostic and prognostic biomarker for cancer, and offers potential in immunomodulatory and targeted therapies.
Authors
- Rui Yu (ORCID: https://orcid.org/0009-0005-5159-1693)
- Hanfei Huang (ORCID: https://orcid.org/0000-0002-0852-9596)
- En-di Zhang
- Bo Yuan (ORCID: https://orcid.org/0000-0003-4437-5368)
- Yunxin Yang
- Zhong Zeng (ORCID: https://orcid.org/0000-0001-9264-4871)
- Chenxuan Li
Institutions
- Kunming Medical University (CN)
- First Affiliated Hospital of Kunming Medical University (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1016/j.tranon.2025.102314
- Citations
- 4
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- National Major Science and Technology Projects of China